Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2006)
10 slides from Resonance Health's shareholder meeting presentation, Nov 17, 2006
Slide 1: Annual General Meeting
Resonance. Resonance Health Limited ACN 006 762 492 Annual General Meeting 17 November 2006
Slide 2: Agenda
Management Strategy - FerriScan® Strategy - Pathology Financial Performance Conclusion
Slide 3: Management
Management Recently hired new management team e Edward D. Dooling, President and CEO — 16 yrs pathology industry experience with several of the most respected companies in the U.S. including DIANON Systems and AmeriPath e Paul Jobbins, CFO — Broad financial and commercial experience including servin
Slide 4: FerriScan®
Strategy - FerriScan® Make FerriScan® product cash flow positive ~ Obtain regulatory clearance in Canada and New Zealand (currently approved in Australia, USA and Europe) ~ 65 MRI sites offering FerriScan® in Australia, NZ, Asia, USA, UK, Europe, Scandinavia and the Middle East; seeking further site
Slide 5: Acquisition of US-based anatomical pathology businesses
Strategy - Pathology Acquisition of US-based anatomical pathology businesses — Complementary to radiology based diagnostic tests — Strengthens access to referral channels — Provides access to US-based billing and operational infrastructure
Slide 6: US based CEO & management team with extensive experience in pathology
Strategy - Pathology — US based CEO & management team with extensive experience in the pathology industry — Acquire a well positioned specialty pathology practice in each of the 30-50 key markets over a 10 year period — Develop each practice into the leading regional provider using: ® Proven sales a
Slide 7: Key Pathology Market Characteristics
Strategy - Pathology Key Pathology Market Characteristics: — Large population centre -— Supports significant long term pathology growth — Within 200 mile radius: e Population of 2,000,000 ® Approximately $40,000,000 in total potential AP Resonance
Slide 8: Initial Pathology Practice Profile
Strategy - Pathology Initial Pathology Practice Profile: — $1million - $10 million in current revenues — 2-6 pathologists — Well regarded for quality and service — Centrally located in key market — Own outpatient lab — Lead by entrepreneurial pathologist — Desire to grow Resonance
Slide 9: Financial Performance
Financial Performance FYO6 Revenue up 118% (year on year) e Re-pricing initiative for FerriScan® product undertaken since August 2006 resulting in improved contractual terms e Revenue increased 133% from 4" quarter FY06 to 1st quarter FY07 e Further operational cost savings in May/June and October 2
Slide 10: Improvement in financial performance
orovement in financial performance e Re-pricing initiative continuing for Ferriscan® e Undertaking diversification strategy e Company well positioned to execute growth strategies
Resonance Health — Shareholder Meeting (November 2006) on 6ix